A former director of Chinook Therapeutics is forcefully denying allegations of insider trading connected to the 2023 acquisition of the kidney disease specialist by Novartis AG. Federal prosecutors in New Jersey have accused Ross Haghighat of participating in a scheme that allegedly generated profits of $600,000.
According to the charges, Haghighat used confidential information obtained during board meetings to inform his associates about the impending takeover. In his defense, the former director contends that the investments made by his acquaintances were based solely on positive analyst coverage and existing interest in the company, suggesting they were merely "riding the wave of public sentiment."
Should investors sell immediately? Or is it worth buying Chinook Therapeutics?
This case highlights the continued and intense regulatory scrutiny of trading activity preceding merger announcements within the biopharmaceutical industry. Markets are historically sensitive to any perceived irregularities, and such legal proceedings underscore the complex regulatory landscape governing major financial transactions.
The indictment is specifically limited to the Chinook transaction and is not related to Haghighat’s previous tenure as Chairman of Sernova Biotherapeutics, a position he left in May 2025. The outcome of this legal dispute is being closely monitored, as events of this nature have the potential to significantly impact investor confidence in the transparency of corporate acquisition processes.
Ad
Chinook Therapeutics Stock: Buy or Sell?! New Chinook Therapeutics Analysis from January 9 delivers the answer:
The latest Chinook Therapeutics figures speak for themselves: Urgent action needed for Chinook Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 9.
Chinook Therapeutics: Buy or sell? Read more here...
